A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients
This phase 1/2 study will evaluate the safety, tolerance and dose of BM7PE treating patients with colorectal cancer who have progressed to standard cell therapy or cannot tolerate such therapy. The study starts as a phase 1 study with the aim of assessing the final dose for this group of patients. Based on the results, the study will continue into a phase 2. The phase 2 study aim to examine overall survival ≥ 9.3 months.
Colorectal Cancer Metastatic
DRUG: BM7PE
Adverse Events related to BM7PE, To characterize the safety and toxicity of BM7PE by register adverse event in accordance with CTCAE 5.0, 30 days after last dose of BM7PE
Efficacy of the BM7PE: Overall survival, The Overall survival will be measured by death registration, Through study completion, an average of 1 year|Efficacy of the BM7PE: progression free survival, The progression free survival will be measured by MR (RECIST 1.1), From date of first treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months|Radiological response to BM7PE, Will be measured by CT (RECIST 1.1) response rate, From date of first treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
This phase 1/2 study will evaluate the safety, tolerance and dose of BM7PE treating patients with colorectal cancer who have progressed to standard cell therapy or cannot tolerate such therapy. The study starts as a phase 1 study with the aim of assessing the final dose for this group of patients. Based on the results, the study will continue into a phase 2. The phase 2 study aim to examine overall survival ≥ 9.3 months.